1
|
Deepa S, Swamy BK, Pai KV. A surfactant SDS modified carbon paste electrode as an enhanced and effective electrochemical sensor for the determination of doxorubicin and dacarbazine its applications: A voltammetric study. J Electroanal Chem (Lausanne) 2020. [DOI: 10.1016/j.jelechem.2020.114748] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
2
|
Intile JL, Rassnick KM, Al-Sarraf R, Chretin JD. Evaluation of the Tolerability of Combination Chemotherapy with Mitoxantrone and Dacarbazine in Dogs with Lymphoma. J Am Anim Hosp Assoc 2019; 55:101-109. [PMID: 30653362 DOI: 10.5326/jaaha-ms-6878] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Combination chemotherapy can be an effective option for treating resistant lymphoma in dogs. This retrospective study examined the tolerability and efficacy of the combination of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (dacarbazine) (DTIC) in a population of dogs with lymphoma resistant to a doxorubicin-containing chemotherapy protocol. Mitoxantrone was administered at 5 mg/m2 IV over 10 min followed by DTIC at 600 mg/m2 IV over 5 hr, every 3 wk. All dogs were treated with prophylactic trimethoprim-sulfadiazine and metoclopramide. The frequency of grade 4 neutropenia was 18%, and 5% of dogs were hospitalized from sepsis. Gastrointestinal toxicity was uncommon. The overall response rate was 34% (15 of 44; 95% confidence interval 20-48%) for a median duration of 97 days (range 24-636 days, 95% confidence interval 44-150 days). Fourteen of 15 dogs who received mitoxantrone and DTIC as first rescue responded to treatment. Dogs who achieved complete remission to their initial L-asparaginase, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol were more likely to respond to mitoxantrone and DTIC (23 versus 11%, P = .035). The combination of mitoxantrone and DTIC is a safe treatment option for resistant lymphoma in dogs.
Collapse
Affiliation(s)
- Joanne L Intile
- From the Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina (J.L.I.); Veterinary Medical Center of Central New York, Syracuse, New York (K.M.R.); Animal Emergency and Referral Associates, Fairfield, New Jersey (R.A-S.); and VCA West Los Angeles Animal Hospital, Los Angeles, California (J.D.C)
| | - Kenneth M Rassnick
- From the Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina (J.L.I.); Veterinary Medical Center of Central New York, Syracuse, New York (K.M.R.); Animal Emergency and Referral Associates, Fairfield, New Jersey (R.A-S.); and VCA West Los Angeles Animal Hospital, Los Angeles, California (J.D.C)
| | - Renee Al-Sarraf
- From the Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina (J.L.I.); Veterinary Medical Center of Central New York, Syracuse, New York (K.M.R.); Animal Emergency and Referral Associates, Fairfield, New Jersey (R.A-S.); and VCA West Los Angeles Animal Hospital, Los Angeles, California (J.D.C)
| | - John D Chretin
- From the Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina (J.L.I.); Veterinary Medical Center of Central New York, Syracuse, New York (K.M.R.); Animal Emergency and Referral Associates, Fairfield, New Jersey (R.A-S.); and VCA West Los Angeles Animal Hospital, Los Angeles, California (J.D.C)
| |
Collapse
|
3
|
Ibrahim M, Temerk Y, Ibrahim H. Fabrication of a new biosensor based on a Sn doped ceria nanoparticle modified glassy carbon paste electrode for the selective determination of the anticancer drug dacarbazine in pharmaceuticals. RSC Adv 2017. [DOI: 10.1039/c7ra04331g] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A new tin doped ceria nanoparticle modified glassy carbon paste electrode (Sn–CeO2NPs/GCPE) was fabricated for the determination of the anticancer drug dacarbazine (DTIC).
Collapse
Affiliation(s)
- Mohamed Ibrahim
- Chemistry Department
- Faculty of Science
- Assiut University
- Assiut 71516
- Egypt
| | - Yassien Temerk
- Chemistry Department
- Faculty of Science
- Assiut University
- Assiut 71516
- Egypt
| | - Hossieny Ibrahim
- Chemistry Department
- Faculty of Science
- Assiut University
- Assiut 71516
- Egypt
| |
Collapse
|
4
|
Rutkauskas K, Zubrienė A, Tumosienė I, Kantminienė K, Kažemėkaitė M, Smirnov A, Kazokaitė J, Morkūnaitė V, Čapkauskaitė E, Manakova E, Gražulis S, Beresnevičius ZJ, Matulis D. 4-amino-substituted benzenesulfonamides as inhibitors of human carbonic anhydrases. Molecules 2014; 19:17356-80. [PMID: 25353386 PMCID: PMC6271771 DOI: 10.3390/molecules191117356] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Revised: 10/14/2014] [Accepted: 10/21/2014] [Indexed: 11/16/2022] Open
Abstract
A series of N-aryl-β-alanine derivatives and diazobenzenesulfonamides containing aliphatic rings were designed, synthesized, and their binding to carbonic anhydrases (CA) I, II, VI, VII, XII, and XIII was studied by the fluorescent thermal shift assay and isothermal titration calorimetry. The results showed that 4-substituted diazobenzenesulfonamides were more potent CA binders than N-aryl-β-alanine derivatives. Most of the N-aryl-β-alanine derivatives showed better affinity for CA II while diazobenzenesulfonamides possessed nanomolar affinities towards CA I isozyme. X-ray crystallographic structures showed the modes of binding of both compound groups.
Collapse
Affiliation(s)
- Kęstutis Rutkauskas
- Department of Organic Chemistry, Kaunas University of Technology, Kaunas LT-50254, Lithuania.
| | - Asta Zubrienė
- Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius University, Graičiūno 8, Vilnius LT-02241, Lithuania.
| | - Ingrida Tumosienė
- Department of Organic Chemistry, Kaunas University of Technology, Kaunas LT-50254, Lithuania.
| | - Kristina Kantminienė
- Department of Physical and Inorganic Chemistry, Kaunas University of Technology, Kaunas LT-50254, Lithuania.
| | - Marytė Kažemėkaitė
- Institute of Biochemistry, Vilnius University, Mokslininkų 12, Vilnius LT-08862, Lithuania.
| | - Alexey Smirnov
- Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius University, Graičiūno 8, Vilnius LT-02241, Lithuania.
| | - Justina Kazokaitė
- Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius University, Graičiūno 8, Vilnius LT-02241, Lithuania.
| | - Vaida Morkūnaitė
- Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius University, Graičiūno 8, Vilnius LT-02241, Lithuania.
| | - Edita Čapkauskaitė
- Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius University, Graičiūno 8, Vilnius LT-02241, Lithuania.
| | - Elena Manakova
- Department of Protein-DNA Interactions, Vilnius University Institute of Biotechnology, Graičiūno 8, Vilnius LT-02241, Lithuania.
| | - Saulius Gražulis
- Department of Protein-DNA Interactions, Vilnius University Institute of Biotechnology, Graičiūno 8, Vilnius LT-02241, Lithuania.
| | | | - Daumantas Matulis
- Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius University, Graičiūno 8, Vilnius LT-02241, Lithuania.
| |
Collapse
|
5
|
Temerk YM, Kamal MM, Ibrahim MS, Ibrahim HSM, Schuhmann W. Electrochemical Behaviour of the Anticancer Dacarbazine-Cu2+ Complex and Its Analytical Applications. ELECTROANAL 2011. [DOI: 10.1002/elan.201100038] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
6
|
Griessmayr PC, Payne SE, Winter JE, Barber LG, Shofer FS. Dacarbazine as single-agent therapy for relapsed lymphoma in dogs. J Vet Intern Med 2009; 23:1227-31. [PMID: 19709354 DOI: 10.1111/j.1939-1676.2009.0376.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Multidrug resistance is the most common cause of treatment failure in dogs with multicentric lymphoma. 5-(3,3-Dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) is an atypical alkylator used as standard treatment in human Hodgkin's lymphoma, and has been effective in combination treatment to treat resistant lymphoma in dogs. However, no data are available on the use of DTIC as a single agent in the treatment of relapsed canine lymphoma. HYPOTHESIS Single-agent DTIC is effective and safe in treating dogs with lymphoma that relapsed or failed to respond to previous chemotherapy. ANIMALS Forty client-owned dogs with relapsed lymphoma. METHODS Dogs were eligible for the retrospective study if they had a histologically or cytologically confirmed diagnosis of lymphoma and had relapsed. Dogs received DTIC (800-1,000 mg/m(2) every 2-3 weeks as a 4-5-hour IV infusion) and were evaluated for response rate and duration. Hematologic and gastrointestinal toxicity was assessed. RESULTS The overall response rate for dogs being treated with DTIC was 35% (14 dogs) with a median progression-free interval of 43 days. Thirteen dogs had a partial response and 1 dog had a complete response. Stable disease was achieved in 3 dogs. Mild gastrointestinal toxicity was reported in 3 dogs posttreatment. Thrombocytopenia was the principal toxicity observed 7-14 days after the treatment. Treatments were delayed because of thrombocytopenia. CONCLUSIONS DTIC, when used alone, is effective in the treatment of dogs with relapsed lymphoma.
Collapse
Affiliation(s)
- P C Griessmayr
- Harrington Oncology Program, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, USA.
| | | | | | | | | |
Collapse
|
7
|
Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res 2007; 13:260-7. [PMID: 17200364 DOI: 10.1158/1078-0432.ccr-06-1920] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE To improve the treatment of women with ovarian cancer, we are investigating the modulation of a prominent DNA-damaging agent, temozolomide, by manipulating the DNA base excision repair (BER) pathway via BER inhibitor, methoxyamine, and overexpression of N-methylpurine DNA glycosylase (MPG). EXPERIMENTAL DESIGN Enhancement of temozolomide via methoxyamine and MPG overexpression was analyzed using in vitro assays, including 3-(4-5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay, apoptosis via Annexin staining, and Western blotting for H2AX phosphorylation to quantitate DNA damage. RESULTS Our data show that we can effectively modulate the activity of the chemotherapeutic agent, temozolomide, via modulator methoxyamine, in three ovarian cancer cell lines, SKOV-3x, Ovcar-3, and IGROV-1. This enhancement of temozolomide-induced cytotoxicity is not dependent on p53 status as we transfected an ovarian cancer cell line with a dominant-negative p53-expressing plasmid (IGROV-1mp53) and obtained similar results. Our results show that MPG-overexpressing IGROV-1 and IGROV-1mp53 cells are significantly more sensitive to the clinical chemotherapeutic temozolomide in combination with methoxyamine as assayed by cytotoxicity, apoptosis, and levels of DNA damage than either agent alone. CONCLUSIONS These studies show that although clinical trials in ovarian cancer to determine temozolomide single-agent efficacy are in development, through manipulation of the BER pathway, an increase in response to temozolomide is achieved. The combination of temozolomide plus methoxyamine has potential for second-line therapy for patients who have failed standard platinum plus paclitaxel chemotherapy.
Collapse
Affiliation(s)
- Melissa L Fishel
- Department of Pediatrics (Section of Hematology/Oncology), Herman B. Wells Center for Pediatric Research, Indianapolis, Indiana 46202, USA
| | | | | | | |
Collapse
|
8
|
Hartinger CG, Ferri-Mendoza MG, Nazarov AA, Keppler BK. Electrospray ionization mass spectrometric study on the coordination behavior of dacarbazine towards transition metal ions. Polyhedron 2006. [DOI: 10.1016/j.poly.2005.12.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Rajkumar SV, Reid JM, Novotny PJ, Safgren SL, Scheithauer BW, Johnson PS, Nair S, Morton RF, Hatfield AK, Krook JE, Ames MM, Buckner JC. A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. J Neurooncol 2000; 49:255-61. [PMID: 11212905 DOI: 10.1023/a:1006454427026] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
We conducted a randomized phase II study to determine the efficacy of dacarbazine (DTIC) in recurrent gliomas. Patients were randomly assigned to receive either DTIC 750 mg/m2 IV day 1 every 28 days (Arm A) or DTIC 200 mg/m2 IV days 1-5 every 28 days (Arm B). Pharmacokinetics were studied in 6 patients on each arm using HPLC analysis. Thirty-nine patients (30 male, 9 female), ages 27-67 years (median 53) were entered on the study (20 on Arm A, 19 on Arm B). No objective responses were seen. Median time to progression was 3 months. Median survival was 8 months. Treatment was generally well tolerated. Major toxicities were grade 1-2 nausea (33%). lethargy (28%), diarrhea (15%), alopecia (15%), and grade 3 neutropenia (8%). Four patients on Arm A had mild self-limited episodes of intravascular hemolysis occurring immediately after drug infusion, the mechanism of which is unknown. Mean AUC for DTIC, HMMTIC (5-[3-hydroxymethyl-3-methyl-1-triazeno] imidazole-4-carboxamide), and MTIC (5-[3-methyl-1-triazenol imidazole-4-carboxamide), in Arm A were 14.8, 0.17, and 1.15 mM min, respectively. Corresponding values for Arm B (on day 1 of 5) were 1.7, 0.06, and 0.29 mM min, respectively. The predicted HMMTIC and MTIC exposure over 5 days for Arm B, based on the day 1 data, is higher than with Arm A. We conclude that DTIC is well tolerated but does not have activity in patients with recurrent gliomas. The 5-day schedule appears less toxic, and pharmacokinetic studies show that it provides greater exposure to MTIC and HMMTIC compared to the one-day schedule.
Collapse
Affiliation(s)
- S V Rajkumar
- Mayo Clinic and Mayo Founccdation, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Mudipalli A, Nadadur SS, Maccubbin AE, Gurtoo HL. Mutations induced by dacarbazine activated with cytochrome P-450. Mutat Res 1995; 327:113-20. [PMID: 7532787 DOI: 10.1016/0027-5107(94)00182-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The mutagenicity of the antitumor drug dacarbazine (DTIC) is due to alkylation of cellular DNA by metabolites resulting from the metabolism of this drug by the mixed function oxidase system. In the present study, we used an in vitro shuttle vector assay to study the base and sequence specificity of mutagenesis by DTIC. The shuttle vector plasmid pSP189 was treated with DTIC (1-2.5 mM) in vitro in a reconstituted cytochrome P-450 system at 37 degrees C for either 30 or 60 min. SupF tRNA gene insert contained in the plasmid was sequenced after replication of the drug-treated plasmid in human Ad 293 cells followed by amplification in indicator bacteria. Mutagenesis of DTIC in this system was dependent upon the presence of the cytochrome P-450 reconstituted system and NADPH. Mutations induced by DTIC included single base substitutions (35%), single base deletions (30.5%), single base insertions (19.4%) and large deletions (13.8%). Among the substitutions, transversions and transitions were in the ratio of 1:0.7. Base pairs 108 and 127 in the SupF tRNA of the pSP189 were identified as mutational hot spots.
Collapse
Affiliation(s)
- A Mudipalli
- Grace Cancer Drug Center, Department of Experimental Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263
| | | | | | | |
Collapse
|
11
|
Nifontov VI, Bel'skaya NP, Shtokareva EA. The reactivity and mechanism of action of triazenes (review). Pharm Chem J 1994. [DOI: 10.1007/bf02219299] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
|
13
|
Rouzer CA, Thompson EJ, Skinner TL, Heavner PA, Bartolini WP, Mitchell K, Kurz E, Smith RH, Michejda CJ. An unexpected pathway for the metabolic degradation of 1,3-dialkyl-3-acyltriazenes. Biochem Pharmacol 1993; 46:165-73. [PMID: 8347127 DOI: 10.1016/0006-2952(93)90361-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
In the presence of NADPH, rat liver microsomes catalyzed the degradation of a series of 1,3-dialkyl-3-acyltriazenes, and the extent of the reaction was correlated with compound lipophilicity. In the case of two methylcarbamoyltriazenes, 1-(2-chloroethyl)-3-benzyl-3- (methylcarbamoyl)triazene (CBzM) and 1-(2-chloroethyl)-3-methyl-3-(methylcarbamoyl)triazene (CMM), microsomal metabolites were isolated. Identification of the CBzM metabolites as 1-(2-chloroethyl)-3-benzyl-3-(hydroxymethylcarbamoyl)triazene and 1-(2-chloroethyl-3-benzyl-3-carbamoyltriazine, and the CMM metabolite as 1-(2-chloroethyl)-3-methyl-3-(hydroxymethylcarbamoyl)triazene indicated that the first metabolic step involves hydroxylation of the methylcarbamoyl substituent. Detailed studies of the metabolism of CBzM indicated that the Km for the reaction was 84 microM, and that metabolism was more efficient if microsomes were prepared from male than from female rats. During prolonged incubation, the metabolites of CBzM were also degraded. The degradation of CBzM and its metabolites was inhibited by SKF-525A and metyrapone, suggesting the involvement of a cytochrome P450 isozyme, and supporting the hypothesis that the process is oxidative rather than hydrolytic in both cases. Metabolic oxidation represents an alternative pathway to chemical or enzymatic hydrolysis for the in vivo decomposition of (methylcarbamoyl)triazenes. This mechanism may ultimately explain the antitumor efficacy and low acute toxicity of selected compounds.
Collapse
Affiliation(s)
- C A Rouzer
- Department of Chemistry, Western Maryland College, Westminster 21157
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Cirrincione G, Almerico AM, Aiello E, Dattolo G, Grimaudo S, Diana P. Synthesis of 3-Triazenopyrroles. SYNTHETIC COMMUN 1993. [DOI: 10.1080/00397919308011259] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Van Vechten M, Helfand SC, Jeglum KA. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine. J Vet Intern Med 1990; 4:187-91. [PMID: 2401965 DOI: 10.1111/j.1939-1676.1990.tb00896.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Fifteen dogs with relapsed lymphoma were treated with doxorubicin and dacarbazine (ADIC) to reinduce remission. All the dogs' lymphomas had become resistant to prior therapy with doxorubicin alone. Five of the 15 dogs had a complete response to the first treatment with ADIC, and three had partial responses. Of the eight dogs receiving a second cycle, two had complete responses, and one had a partial response. One dog that received a third ADIC treatment no longer responded. The median survival time from the first ADIC treatment for all dogs was 45 days (range, 18-241 days). The five dogs having complete responses to the first ADIC treatment had a median survival time of 105 days (range, 45-241 days) after this treatment. Toxicity due to ADIC treatment was acceptable and did not exceed that seen when doxorubicin was given as a single agent. The treatment resulted in severe neutropenia in three dogs. One dog died due to neutropenic sepsis. Vomiting, diarrhea, and anorexia occurred, but were tolerable, resulting in hospitalization in only one instance. ADIC is apparently a useful chemotherapeutic combination to reinduce remission in some dogs with relapsed lymphoma.
Collapse
Affiliation(s)
- M Van Vechten
- Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia
| | | | | |
Collapse
|
16
|
|